Skip to main content
. 2020 Dec 15;14(2):100984. doi: 10.1016/j.tranon.2020.100984

Fig. 5.

Fig 5

Extent of (A) cluster of differentiation (CD)−4+ and (B) CD16+ T-cell infiltration in tumor biopsies at baseline and during treatment (day 29) with vanucizumab for patients with a documented best overall response of progressive disease (PD) or stable disease (SD)a. aNon-paired data points are shown for completeness where data points are missing.